Make your own free website on Tripod.com
Home | 2003 (1997-2003) Cover Shorty | Inside cover | News 11-04 | News 6-04 | Current stock holdings | Election results | Stock from the company | Stock givers /traders | Profit and loss | Balance sheet 2003 | Balance sheet 2000 | RE, S&U, bank stmts 2003 | RE, S&U, bank stmts 2000 | News & history first half 2004 | Dr. Peebles' story | News & history 2001 - 2003 | News & history 1997 - 2000 | Owners like Pfizer strategy | Wal-Mart strategy | Pedi-sales strategy | Celgene takeover of pediatric drugs strategy | Device maker strategy | Your choice for licensing strategies | Ballot | Expenses graph | Expense report 2003 | Goodwill report 2003 | Contacts
Prophy Research Corporation reports

Owners like Pfizer strategy

The most likely and least interesting licensing strategy will be to simply approach each of the owners of the most popular products and offer them a license for their specific product. Like for infant fluoride, approach Mead Johnson (Poly-Vi-Flor); for acetaminophen, approach McNeil (Tylenol), etc. These people have worked long and hard to develop and maintain their good products, and deserve the first shot at any new changes. In some cases (like Mead), they have helped us with things like making our prototype droppers, answering questions, etc.

 

Let’s take a quick look at one of the owners, Pfizer. The advantages of Pfizer as a licensee:

 

They are very interested in “product enhancements” – features they can add to drugs that are going off patent very soon.  A good example is their antibiotic Zithromax. It will go off patent in less than a year (11-05). It would be an ideal candidate for dosing by weight (they have done it already in Belgium, see the world list on inside cover page). They have one enhancement (at least) on Zithromax so far, a “sustained release” version under patent.  (See WSJ articles 8-23-04, 12-1-04.)

 

They even have a separate group that looks for things just like OptiDose:

http://www.pfizer.com/subsites/psig/index.html

If we succeeded in giving Pfizer a good enhancement on Zithromax, it would almost surely be the biggest and most immediate value we could create with the patent. The longer and broader prospects would also be good – Pfizer has many other products facing generic competition very soon.

 
 

If there is no interest from the owners, then we can look at some other strategies. Here is a fun list if you want to look.

Wal-Mart strategy

Pedi-sales strategy

Celgene takeover of pediatric drugs strategy